Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
41
OXBDF Quote, Financials, Valuation and Earnings
Last price:
$8.15
Seasonality move
:
5.68%
Day range:
$8.12 - $8.30
52-week range:
$3.15 - $8.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.40x
P/B ratio:
9.28x
Volume:
40.3K
Avg. volume:
5.3K
1-year change:
51.78%
Market cap:
$976.1M
Revenue:
$164.6M
EPS (TTM):
-$0.47
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Oxford Biomedica Plc has -- downside to fair value with a price target of -- per share.
OXBDF vs. S&P 500
-
Over the past 5 trading days, Oxford Biomedica Plc has underperformed the S&P 500 by -0.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Oxford Biomedica Plc does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Oxford Biomedica Plc has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Oxford Biomedica Plc reported revenues of --.
Earnings Growth
-
Oxford Biomedica Plc has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Oxford Biomedica Plc reported earnings per share of --.
Enterprise value:
642.6M
EV / Invested capital:
--
Price / LTM sales:
4.40x
EV / EBIT:
--
EV / Revenue:
3.92x
PEG ratio (5yr expected):
-6.30x
EV / Free cash flow:
-8.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$85.9M
Return On Assets:
-46.7%
Net Income Margin (TTM):
-25.87%
Return On Equity:
-120.93%
Return On Invested Capital:
-90.47%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2017-12-31 | 2018-12-31 | |
| Income Statement | ||||||
| Revenue | $36.9M | $49.1M | $88.6M | -- | -- | |
| Gross Profit | $21.3M | $25M | $45M | -- | -- | |
| Operating Income | -$15.4M | -$10.4M | $10.9M | -- | -- | |
| EBITDA | -$15.6M | $2.7M | $20.9M | -- | -- | |
| Diluted EPS | -$0.41 | -$0.19 | $0.15 | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $171.5M | $246.1M | $224.1M | $175.7M | -- | |
| Total Assets | $273.6M | $566.1M | $505.9M | $309.8M | -- | |
| Current Liabilities | $65.4M | $134.4M | $67.5M | $74.8M | -- | |
| Total Liabilities | $90.1M | $250.7M | $255.9M | $219.8M | -- | |
| Total Equity | $183.5M | $315.4M | $249.9M | $90.1M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2024-12-31 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.4M | -$65.4M | -- | -- | -- | |
| Cash From Investing | -$1.8M | $1.9M | -- | -- | -- | |
| Cash From Financing | -$10.7M | $9M | -- | -- | -- | |
| Free Cash Flow | -$47.7M | -$75M | -- | -- | -- | |
OXBDF
Sector
Market Cap
$976.1M
$27.9M
Price % of 52-Week High
93.33%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-0.28%
-1.55%
1-Year Price Total Return
51.78%
-17.49%
Beta (5-Year)
1.121
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.22
200-day SMA
Buy
Level
$6.06
Bollinger Bands (100)
Buy
Level
7.22 - 8.56
Chaikin Money Flow
Sell
Level
-116K
20-day SMA
Sell
Level
$8.31
Relative Strength Index (RSI14)
Sell
Level
39.29
ADX Line
Sell
Level
15.02
Williams %R
Buy
Level
-95.8212
50-day SMA
Sell
Level
$8.35
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Sell
Level
-45.3K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.4946)
Sell
CA Score
(Annual)
Level (-2.1791)
Sell
Beneish M-Score
(Annual)
Level (-1.1594)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.3218)
Sell
Piotroski F Score
(Annual)
Level (3)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.
Stock Forecast FAQ
In the current month, OXBDF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OXBDF average analyst price target in the past 3 months is --.
-
Where Will Oxford Biomedica Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Oxford Biomedica Plc share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Oxford Biomedica Plc?
Analysts are divided on their view about Oxford Biomedica Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Oxford Biomedica Plc is a Sell and believe this share price will rise from its current level to --.
-
What Is Oxford Biomedica Plc's Price Target?
The price target for Oxford Biomedica Plc over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OXBDF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Oxford Biomedica Plc is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of OXBDF?
You can purchase shares of Oxford Biomedica Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Oxford Biomedica Plc shares.
-
What Is The Oxford Biomedica Plc Share Price Today?
Oxford Biomedica Plc was last trading at $8.15 per share. This represents the most recent stock quote for Oxford Biomedica Plc. Yesterday, Oxford Biomedica Plc closed at $8.12 per share.
-
How To Buy Oxford Biomedica Plc Stock Online?
In order to purchase Oxford Biomedica Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get OXBDF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OXBDF
Sector
P/E ratio
--
23.75x
PEG ratio
-6.30x
-0.01x
P/B ratio
9.28x
1.81x
Price / LTM sales
4.40x
1.59x
Growth Metrics
OXBDF
Sector
Revenue growth
--
4.6%
Earnings growth
--
10.88%
Revenue (5-year growth)
15.03%
6.45%
Earnings forecast
--
-$0.21
Profitability
OXBDF
Sector
Profitability FY 2024
$66.9M
$3.6M
Return on invested capital
-90.47%
-31.84%
Return on assets
-46.7%
-27.96%
Return on equity
-120.93%
-37.63%
Earnings Date
Last Earnings Date
Sep
23
Next Earnings Date
Apr
9
Estimated Next Earnings Date
Dec
23
Balance Sheet
OXBDF
Sector
Total cash
$103M
$26.3M
Short term investments
--
$25.7M
Total assets
$290.1M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
